Capricor Therapeutics 향후 성장

Future 기준 점검 5/6

Capricor Therapeutics은 연간 수입과 매출이 각각 60.6%와 46% 증가할 것으로 예상되고 EPS는 연간 61.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

60.6%

이익 성장률

61.13%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	46.0%
향후 자기자본이익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	17 Dec 2025

최근 향후 성장 업데이트

Recent updates

Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court

Dec 03

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Nov 05

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Sep 09

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 24

Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

May 16

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

May 09

FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel

May 03 FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.

New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Mar 29

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Mar 19

Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Dec 12

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Dec 06

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Sep 18

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

Jul 30

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13

이익 및 매출 성장 예측

NasdaqCM:CAPR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	261	95	148	N/A	5
12/31/2027	160	29	70	N/A	5
12/31/2026	128	-3	34	141	10
12/31/2025	1	-100	-106	-85	10
9/30/2025	11	-82	-68	-61	N/A
6/30/2025	13	-70	-56	-53	N/A
3/31/2025	17	-55	-47	-45	N/A
12/31/2024	22	-40	-42	-40	N/A
9/30/2024	23	-34	-38	-37	N/A
6/30/2024	27	-28	-36	-34	N/A
3/31/2024	27	-24	-33	-31	N/A
12/31/2023	25	-22	-28	-26	N/A
9/30/2023	14	-29	-23	-21	N/A
6/30/2023	9	-29	-21	-18	N/A
3/31/2023	6	-29	-18	-15	N/A
12/31/2022	3	-29	2	5	N/A
9/30/2022	2	-27	4	6	N/A
6/30/2022	N/A	-25	7	9	N/A
3/31/2022	0	-23	9	11	N/A
12/31/2021	0	-20	-18	-17	N/A
9/30/2021	0	-18	-16	-15	N/A
6/30/2021	0	-18	-15	-15	N/A
3/31/2021	0	-17	-13	-12	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-11	-8	-8	N/A
6/30/2020	1	-9	-7	-7	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-9	-9	-9	N/A
6/30/2019	2	-12	N/A	-10	N/A
3/31/2019	2	-14	N/A	-12	N/A
12/31/2018	2	-15	N/A	-14	N/A
9/30/2018	1	0	N/A	-13	N/A
6/30/2018	2	2	N/A	-13	N/A
3/31/2018	2	2	N/A	-13	N/A
12/31/2017	3	2	N/A	-14	N/A
9/30/2017	3	-14	N/A	-15	N/A
6/30/2017	4	-17	N/A	-14	N/A
3/31/2017	4	-18	N/A	-15	N/A
12/31/2016	4	-19	N/A	-14	N/A
9/30/2016	4	-18	N/A	-15	N/A
6/30/2016	5	-15	N/A	-16	N/A
3/31/2016	5	-14	N/A	-13	N/A
12/31/2015	6	-13	N/A	-11	N/A
9/30/2015	6	-11	N/A	-9	N/A
6/30/2015	6	-10	N/A	-8	N/A
3/31/2015	6	-8	N/A	-12	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CAPR 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.3%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: CAPR (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: CAPR 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: CAPR 의 수익(연간 46%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CAPR 의 수익(연간 46%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CAPR의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 11:06
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Capricor Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Matthew Venezia	Alliance Global Partners
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Kristen Kluska	Cantor Fitzgerald & Co.

Capricor Therapeutics 향후 성장

Future 기준 점검 5/6

핵심 정보

최근 향후 성장 업데이트

Forecast to breakeven in 2027

Consensus revenue estimates decrease by 50%

Consensus revenue estimates fall by 45%

Consensus revenue estimates fall by 51%

Forecast breakeven date moved forward to 2025

Consensus revenue estimates increase by 64%

Recent updates

Capricor Therapeutics Announces Positive Topline Results From Phase 3 HOPE-3 Trial Of Deramiocel For Duchenne Muscular Dystrophy

New minor risk - Shareholder dilution

Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Forecast to breakeven in 2027

New major risk - Share price stability

Capricor Therapeutics, Inc. Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court

Capricor Therapeutics, Inc. Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes

Consensus revenue estimates decrease by 50%

Third quarter 2025 earnings released: US$0.54 loss per share (vs US$0.38 loss in 3Q 2024)

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc. to Report Q3, 2025 Results on Nov 10, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter for Deramiocel

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

Consensus revenue estimates fall by 45%

First half 2025 earnings released: US$1.10 loss per share (vs US$0.66 loss in 1H 2024)

Capricor Therapeutics, Inc. to Report Q2, 2025 Results on Aug 11, 2025

Levi & Korsinsky, LLP Notifies Investors in Capricor Therapeutics, Inc. of A Class Action Securities Law

Consensus revenue estimates fall by 51%

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc.(NasdaqCM:CAPR) dropped from Russell 3000E Value Index

Forecast breakeven date moved forward to 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Capricor Therapeutics Announces Positive 4-Year Data from Hope-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces the Successful Completion of the U.S. Food and Drug Administration's License Inspection of Its San Diego Manufacturing Facility

Capricor Therapeutics Announces Key Regulatory Updates for Its Duchenne Muscular Dystrophy Program

Consensus revenue estimates increase by 64%

Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair

Forecast breakeven date pushed back to 2027

Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

New major risk - Share price stability

Capricor Therapeutics, Inc. to Report Q1, 2025 Results on May 13, 2025

FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel

Capricor Therapeutics, Inc., Annual General Meeting, May 22, 2025

Earl Collier Not to Stand for Re-Election as Member of the Board of Capricor Therapeutics, Inc

New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Capricor Therapeutics, Inc. Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. to Report Q4, 2024 Results on Mar 19, 2025

Capricor Therapeutics Announces FDA Acceptance and Priority Review of Its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

New major risk - Shareholder dilution

Capricor Therapeutics Completes Submission of Biologics License Application to U.S. FDA for Deramiocel for Treatment of Duchenne Muscular Dystrophy

Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding

Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

New major risk - Shareholder dilution

Capricor Therapeutics, Inc. Intends to File A Biologics License Application

Capricor Therapeutics, Inc. has filed a Follow-on Equity Offering.

Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Price target increased by 28% to US$25.40

Forecast to breakeven in 2026

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd.

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Consensus revenue estimates fall by 16%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel

New major risk - Financial position

Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Profitability